Haystack Oncology specializes in high-precision minimal residual disease (MRD) testing, utilizing advanced technologies to detect ultralow levels of circulating tumor DNA (ctDNA). Their flagship product, Haystack MRD™, is a tumor-informed, next-generation test designed to uncover residual disease following definitive surgery. This technology not only enhances the sensitivity of ctDNA detection but also allows for improved risk assessment for adjuvant chemotherapy, enabling clinicians to make more informed treatment decisions. By tracking ctDNA levels during chemotherapy, Haystack MRD™ facilitates the monitoring of treatment responses and the early detection of disease recurrence, thereby optimizing patient management.

The development of Haystack MRD™ is rooted in over 20 years of research in liquid biopsy and cancer genomics, reflecting a commitment to transformative precision oncology. The test is backed by the operational capabilities of Quest Diagnostics, ensuring end-to-end reliability in MRD testing through credentialed staff, advanced laboratories, and streamlined logistics. This partnership allows for a seamless transition between Haystack MRD™ and other advanced oncology tests, enhancing the overall patient care experience. By focusing on exquisite sensitivity and confident MRD results, Haystack Oncology aims to significantly improve patient outcomes and support clinicians and biopharma in their therapeutic development efforts.

United States

Haystack MRD™ by Quest Diagnostics is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after cancer treatment. Based on more than 20 years of clinical development and technology from pioneers in cancer genomics at Johns Hopkins University, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help inform treatment decision-making.

Haystack Oncology

Company Details